Arcturus Therapeutics Holdings (ARCT) Cash & Current Investments (2018 - 2026)

Arcturus Therapeutics Holdings has reported Cash & Current Investments for 9 years, with the latest figure at $211.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 17.25% year-over-year to $211.4 million; the trailing twelve-month figure through Mar 2026 stood at $211.4 million (down 17.25% YoY), and the FY2025 full-year result was $230.9 million, down 33.82% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $211.4 million, down from $230.9 million in the prior quarter.
• The five-year high for Cash & Current Investments was $391.9 million in Q4 2022, with the low at $211.4 million in Q1 2026.
• Historically, Cash & Current Investments has averaged $295.7 million across 5 years, with a median of $311.9 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Current Investments tumbled 42.57% — and 2023, when it surged 31.24%.
• Arcturus Therapeutics Holdings' Cash & Current Investments stood at $391.9 million in 2022, then fell by 11.45% to $347.0 million in 2023, then rose by 0.55% to $348.9 million in 2024, then slumped by 33.82% to $230.9 million in 2025, then declined by 8.46% to $211.4 million in 2026.
• The last three Cash & Current Investments figures came in at $211.4 million (Q1 2026), $230.9 million (Q4 2025), and $235.4 million (Q3 2025), per Business Quant data.